2,237 results on '"Berdel, Wolfgang E"'
Search Results
2. Multiparametric MRI for characterization of the tumour microenvironment
3. Prognostic impact of CEBPA mutational subgroups in adult AML
4. Remission induction versus immediate allogeneic haematopoietic stem cell transplantation for patients with relapsed or poor responsive acute myeloid leukaemia (ASAP): a randomised, open-label, phase 3, non-inferiority trial
5. Sex-associated differences in frequencies and prognostic impact of recurrent genetic alterations in adult acute myeloid leukemia (Alliance, AMLCG)
6. Mutated IKZF1 is an independent marker of adverse risk in acute myeloid leukemia
7. Secondary-type mutations do not impact outcome in NPM1-mutated acute myeloid leukemia – implications for the European LeukemiaNet risk classification
8. CAR T cells as micropharmacies against solid cancers: Combining effector T-cell mediated cell death with vascular targeting in a one-step engineering process
9. UBTF tandem duplications are rare but recurrent alterations in adult AML and associated with younger age, myelodysplasia, and inferior outcome
10. Unsupervised meta-clustering identifies risk clusters in acute myeloid leukemia based on clinical and genetic profiles
11. Alterations of cohesin complex genes in acute myeloid leukemia: differential co-mutations, clinical presentation and impact on outcome
12. Targeted siRNA nanocarrier: a platform technology for cancer treatment
13. Deep learning predicts therapy-relevant genetics in acute myeloid leukemia from Pappenheim-stained bone marrow smears
14. Amsacrine-based induction therapy in AML patients with cardiac comorbidities: a retrospective single-center analysis
15. Different treatment strategies versus a common standard arm (CSA) in patients with newly diagnosed AML over the age of 60 years: a randomized German inter-group study
16. Germ line variant GFI1-36N affects DNA repair and sensitizes AML cells to DNA damage and repair therapy
17. A randomized phase 2 trial of nintedanib and low-dose cytarabine in elderly patients with acute myeloid leukemia ineligible for intensive chemotherapy
18. Using stroma-anchoring cytokines to augment ADCC: a phase 1 trial of F16IL2 and BI 836858 for posttransplant AML relapse
19. Impact of IDH1 and IDH2 mutational subgroups in AML patients after allogeneic stem cell transplantation
20. Molecular profiling and clinical implications of patients with acute myeloid leukemia and extramedullary manifestations
21. Electrostatic anti-CD33-antibody–protamine nanocarriers as platform for a targeted treatment of acute myeloid leukemia
22. Differential impact of IDH1/2 mutational subclasses on outcome in adult AML: results from a large multicenter study
23. CEBPA mutations in 4708 patients with acute myeloid leukemia: differential impact of bZIP and TAD mutations on outcome
24. The role of autologous stem cell transplantation (ASCT) in aggressive B-cell lymphomas: real-world data from a retrospective single-center analysis
25. A clinically applicable gene expression–based score predicts resistance to induction treatment in acute myeloid leukemia
26. Friday leukemia—a structural phenomenon
27. Remission induction versus immediate allogeneic haematopoietic stem cell transplantation for patients with relapsed or poor responsive acute myeloid leukaemia (ASAP): a randomised, open-label, phase 3, non-inferiority trial
28. Impact of PTPN11 mutations on clinical outcome analyzed in 1529 patients with acute myeloid leukemia
29. Obituary Prof. Dr. med. Johann Rastetter (28th of March 1928–23rd of June 2022)—a leading German hematologist
30. Magnesium levels and outcome after allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia
31. Hotspot DNMT3A mutations in clonal hematopoiesis and acute myeloid leukemia sensitize cells to azacytidine via viral mimicry response
32. Calcitonin receptor-like (CALCRL) is a marker of stemness and an independent predictor of outcome in pediatric AML
33. Prognostic impact of CEBPA mutational subgroups in adult AML
34. Deep learning predicts therapy-relevant genetics in acute myeloid leukemia from Pappenheim-stained bone marrow smears
35. Sex-associated differences in frequencies and prognostic impact of recurrent genetic alterations in adult acute myeloid leukemia (Alliance, AMLCG)
36. Prevalence and clinical impact of CD56 and T‐cell marker expression in acute myeloid leukaemia: A single‐centre retrospective analysis
37. Validation and refinement of the revised 2017 European LeukemiaNet genetic risk stratification of acute myeloid leukemia
38. Author Correction: Loss-of-function uORF mutations in human malignancies
39. Integrated RNAi screening identifies the NEDDylation pathway as a synergistic partner of azacytidine in acute myeloid leukemia
40. Clinical presentation and differential splicing of SRSF2, U2AF1 and SF3B1 mutations in patients with acute myeloid leukemia
41. Monitoring minimal residual/relapsing disease after allogeneic haematopoietic stem cell transplantation in adult patients with acute lymphoblastic leukaemia
42. The clinical mutatome of core binding factor leukemia
43. The neuropeptide receptor calcitonin receptor-like (CALCRL) is a potential therapeutic target in acute myeloid leukemia
44. Prevalence and clinical impact of CD56 and T‐cell marker expression in acute myeloid leukaemia: A single‐centre retrospective analysis.
45. Germline variant GFI1-36N affects DNA repair and sensitizes AML cells to DNA damage and repair therapy
46. P446: COMPREHENSIVE CHARACTERIZATION OF DIFFERENTIAL GENE EXPRESSION AND ISOFORM USAGE IN SPLICING FACTOR-MUTATED ACUTE MYELOID LEUKEMIA USING LONG-READ SEQUENCING
47. P434: MYELODYSPLASIA-RELATED MUTATIONS IN THE NEW ELN CLASSIFICATION: DOES CLONAL SIZE PLAY A ROLE?
48. P457: COMPLEX CARYOTYPE IS AN INDEPENDENT RISK FACTOR IN TP53-MUTATED AML
49. Long-term efficacy of reduced-intensity versus myeloablative conditioning before allogeneic haemopoietic cell transplantation in patients with acute myeloid leukaemia in first complete remission: retrospective follow-up of an open-label, randomised phase 3 trial
50. The beginning of the end for conventional RECIST — novel therapies require novel imaging approaches
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.